If you aim to lose weight or reduce the risk of kidney or cardiovascular disease, semaglutide is more suitable as the medication is FDA-approved for this purpose
Each receptor subtype serves different functions in the body, so activating all of them simultaneously produces effects across skin, brain, gut, and cardiovascular systems
It has also been found that, in addition to effectively treating diabetes and obesity, semaglutide, tirzepatide, and similar drugs reduce the risk of heart attacks, strokes, and death from cardiovascular causes by 20%
Testing Schedule Obtain baseline bloodwork 2 to 4 weeks before beginning the protocol
Our protocol integrates laboratory medicine, body composition analysis, and metabolic coaching to maximize safety and outcomes. Before starting GLP-1 therapy, we recommend a comprehensive metabolic workup that includes: Fasting glucose and insulin: Establishes baseline glucose control and HOMA-IR (insulin resistance index) HbA1c: 3-month glucose average